NASDAQ : CMND
Clearmind Medicine Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 5.85 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.62M |
| Enterprise Value | -11.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 420,883 |
| Shares Outstanding | 420,883 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +423.95% |
| Owned by Insiders (%) | 6.42% |
| Owned by Institutions (%) | 1.46% |
| Float | 393,865 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.13 |
| P/TBV Ratio | 0.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.31 |
| Quick Ratio | 4.28 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,196.98 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -106.98% |
| Return on Assets (ROA) | -53.08% |
| Return on Invested Capital (ROIC) | -69.96% |
| Return on Capital Employed (ROCE) | -67.93% |
| Weighted Average Cost of Capital (WACC) | 4.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 12,695 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -98.06% |
| 50-Day Moving Average | 8.08 |
| 200-Day Moving Average | 11.84 |
| Relative Strength Index (RSI) | 43.36 |
| Average Volume (20 Days) | 22,430 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3,861 |
| Short Previous Month | 14,819 |
| Short % of Shares Out | 0.92% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 0.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.87M |
| Pretax Income | -7.48M |
| Net Income | -7.50M |
| EBITDA | -8.86M |
| EBIT | -8.87M |
| Earnings Per Share (EPS) | -$118.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 15.93M |
| Total Debt | 1.80M |
| Net Cash | 14.13M |
| Net Cash Per Share | $33.58 |
| Equity (Book Value) | 12.95M |
| Book Value Per Share | 48.30 |
| Working Capital | 12.77M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.07M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 10,954 |
| Net Borrowing | 10.08M |
| Free Cash Flow | -7.07M |
| FCF Per Share | -$16.80 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1,904.04% |
| FCF Yield | -270.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 5, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |